Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy

The Nebraska Lymphoma Study Group Experience

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: The aim of the study was to determine the outcome and clinical features predictive of survival in patients with follicular lymphoma (FL) treated aggressively and to determine the rate of disease-specific mortality in patients with grade 3 FL (FL3). Materials and methods: Four hundred and twenty-one patients with FL who were treated with various anthracycline-based chemotherapy regimens were included in this retrospective study. Results: Patients with FL3 and a diffuse component of >50% had the worst outcome, with a hazard ratio of dying of 2.2 (95% CI 1.4-3.4) compared with patients with FL1 or FL2, and a ratio of 1.6 (95% CI 1.02-2.5) compared with FL3 with a diffuse component of ≤50% by multivariate analysis (P = 0.0026). Patients with FL3a had an outcome similar to those with FL3b. In patients with FL3 and a diffuse component of ≤50%, the overall and event-free survival curves showed a plateau for patients younger than 60 years of age. However, there were no differences in the cumulative incidence of relapse/progression or lymphoma-specific/treatment-related mortality between the two age groups. Conclusions: Less than half of the patients with FL3 and a diffuse component of ≤50% treated with anthracycline-based combination chemotherapy will relapse and relapses are uncommon after 6 years. Older patients should be offered the same aggressive chemotherapy as younger patients.

Original languageEnglish (US)
Pages (from-to)920-927
Number of pages8
JournalAnnals of Oncology
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2006

Fingerprint

Follicular Lymphoma
Anthracyclines
Lymphoma
Recurrence
Drug Therapy
Survival
Mortality
Combination Drug Therapy
Disease-Free Survival
Multivariate Analysis
Retrospective Studies
Age Groups

Keywords

  • Age
  • Anthracyclines
  • Grade 3 follicular lymphoma
  • Outcomes
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{883bcecb5e68431e80da0defa2d49b9b,
title = "Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska Lymphoma Study Group Experience",
abstract = "Background: The aim of the study was to determine the outcome and clinical features predictive of survival in patients with follicular lymphoma (FL) treated aggressively and to determine the rate of disease-specific mortality in patients with grade 3 FL (FL3). Materials and methods: Four hundred and twenty-one patients with FL who were treated with various anthracycline-based chemotherapy regimens were included in this retrospective study. Results: Patients with FL3 and a diffuse component of >50{\%} had the worst outcome, with a hazard ratio of dying of 2.2 (95{\%} CI 1.4-3.4) compared with patients with FL1 or FL2, and a ratio of 1.6 (95{\%} CI 1.02-2.5) compared with FL3 with a diffuse component of ≤50{\%} by multivariate analysis (P = 0.0026). Patients with FL3a had an outcome similar to those with FL3b. In patients with FL3 and a diffuse component of ≤50{\%}, the overall and event-free survival curves showed a plateau for patients younger than 60 years of age. However, there were no differences in the cumulative incidence of relapse/progression or lymphoma-specific/treatment-related mortality between the two age groups. Conclusions: Less than half of the patients with FL3 and a diffuse component of ≤50{\%} treated with anthracycline-based combination chemotherapy will relapse and relapses are uncommon after 6 years. Older patients should be offered the same aggressive chemotherapy as younger patients.",
keywords = "Age, Anthracyclines, Grade 3 follicular lymphoma, Outcomes, Therapy",
author = "Ganti, {Apar Kishor P} and Weisenburger, {D. D.} and Smith, {Lynette M} and Hans, {C. P.} and Bociek, {Robert G} and Bierman, {Philip Jay} and Vose, {Julie Marie} and Armitage, {James Olen}",
year = "2006",
month = "6",
day = "1",
doi = "10.1093/annonc/mdl039",
language = "English (US)",
volume = "17",
pages = "920--927",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy

T2 - The Nebraska Lymphoma Study Group Experience

AU - Ganti, Apar Kishor P

AU - Weisenburger, D. D.

AU - Smith, Lynette M

AU - Hans, C. P.

AU - Bociek, Robert G

AU - Bierman, Philip Jay

AU - Vose, Julie Marie

AU - Armitage, James Olen

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Background: The aim of the study was to determine the outcome and clinical features predictive of survival in patients with follicular lymphoma (FL) treated aggressively and to determine the rate of disease-specific mortality in patients with grade 3 FL (FL3). Materials and methods: Four hundred and twenty-one patients with FL who were treated with various anthracycline-based chemotherapy regimens were included in this retrospective study. Results: Patients with FL3 and a diffuse component of >50% had the worst outcome, with a hazard ratio of dying of 2.2 (95% CI 1.4-3.4) compared with patients with FL1 or FL2, and a ratio of 1.6 (95% CI 1.02-2.5) compared with FL3 with a diffuse component of ≤50% by multivariate analysis (P = 0.0026). Patients with FL3a had an outcome similar to those with FL3b. In patients with FL3 and a diffuse component of ≤50%, the overall and event-free survival curves showed a plateau for patients younger than 60 years of age. However, there were no differences in the cumulative incidence of relapse/progression or lymphoma-specific/treatment-related mortality between the two age groups. Conclusions: Less than half of the patients with FL3 and a diffuse component of ≤50% treated with anthracycline-based combination chemotherapy will relapse and relapses are uncommon after 6 years. Older patients should be offered the same aggressive chemotherapy as younger patients.

AB - Background: The aim of the study was to determine the outcome and clinical features predictive of survival in patients with follicular lymphoma (FL) treated aggressively and to determine the rate of disease-specific mortality in patients with grade 3 FL (FL3). Materials and methods: Four hundred and twenty-one patients with FL who were treated with various anthracycline-based chemotherapy regimens were included in this retrospective study. Results: Patients with FL3 and a diffuse component of >50% had the worst outcome, with a hazard ratio of dying of 2.2 (95% CI 1.4-3.4) compared with patients with FL1 or FL2, and a ratio of 1.6 (95% CI 1.02-2.5) compared with FL3 with a diffuse component of ≤50% by multivariate analysis (P = 0.0026). Patients with FL3a had an outcome similar to those with FL3b. In patients with FL3 and a diffuse component of ≤50%, the overall and event-free survival curves showed a plateau for patients younger than 60 years of age. However, there were no differences in the cumulative incidence of relapse/progression or lymphoma-specific/treatment-related mortality between the two age groups. Conclusions: Less than half of the patients with FL3 and a diffuse component of ≤50% treated with anthracycline-based combination chemotherapy will relapse and relapses are uncommon after 6 years. Older patients should be offered the same aggressive chemotherapy as younger patients.

KW - Age

KW - Anthracyclines

KW - Grade 3 follicular lymphoma

KW - Outcomes

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33646861927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646861927&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdl039

DO - 10.1093/annonc/mdl039

M3 - Article

VL - 17

SP - 920

EP - 927

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -